A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the … (NCT07534813) | Clinical Trial Compass
WithdrawnNot Applicable
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors
Stopped: Due to procedural adjustments at the investigative site, domestic registration on the China health authority's platform must be finalized prior to re-submission on ClinicalTrials.gov. Therefore, we hereby withdraw the current submission.
China0Started 2026-04-30
Plain-language summary
This study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and determine the optimal dosage regimen.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Routine blood tests: reference ranges are provided below, and final judgment may be made by the investigator considering variations in normal reference ranges across central laboratories:
. Liver function tests: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN; total bilirubin (TBIL) ≤ 1.5 × ULN. Criteria may be relaxed under the following conditions:
. Renal function tests: creatinine clearance (CrCL) ≥ 45 mL/min (calculated using the Cockcroft-Gault formula), or serum creatinine (Cr) within normal range; and urine protein (Pro) \< 2+.
. Coagulation function tests: APTT ≤ 1.5 × ULN, and international normalized ratio (INR) or PT ≤ 1.5 × ULN.
. Good cardiac function.
. Good pulmonary function.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1I saw a trial called GT307 using tumor-infiltrating lymphocytes for advanced solid tumors, but it shows as 'Withdrawn' — can you tell me why it was withdrawn, and whether there are any similar TIL therapy trials that are still actively enrolling?
2Since this study was focusing on safety and tolerability of GT307 rather than effectiveness, what does that tell us about how much is currently known about this type of treatment, and how does that compare to other options available to me right now?
3TIL therapy like GT307 requires removing immune cells from a patient's own tumor — can you explain what that process would have involved, and whether any centers near us are running comparable cell therapy studies for my type of cancer?
4Given that this trial was withdrawn before completing, should I be looking at standard treatments first, or is there a strong enough rationale for me to prioritize finding another experimental immunotherapy trial at this stage?
5Are there other autologous cell therapy or TIL-based trials for metastatic solid tumors that you would consider worth exploring for my specific situation, given that this particular study is no longer an option?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Evaluation of the safety of GT307 in the treatment of advanced solid tumors
Timeframe: 24 months
2
Evaluation of the tolerability of GT307 in the treatment of advanced solid tumors